title: [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
abstract: Besides percutaneous coronary interventions, antiplatelet drugs are of overwhelming importance for patients with acute coronary syndrome (ACS). For ACS patients, the guidelines recommend treatment with acetylsalicylic acid and a P2Y12 receptor antagonist. The third generation P2Y12 receptor antagonists prasugrel and ticagrelor provide stronger platelet inhibition than clopidogrel and improve the clinical outcome in patients with ACS; however, it is still under discussion which P2Y12 antagonist fits best to which subgroup of ACS patients. This article summarizes current guidelines and antiplatelet treatment strategies for patients with non-ST-segment elevation (NSTE) ACS or ST-segment elevation myocardial infarction (STEMI). The information is mainly based on the recently published guidelines of the European Society of Cardiology on myocardial revascularization.
authors.affiliation: Universitäts-Herzzentrum, Klinik für Kardiologie und Angiologie I, Universität Freiburg, Hugstetter Str. 55, 79106, Freiburg, Deutschland, Christoph.Olivier@universitaets-herzzentrum.de.
authors.forename: C B
authors.initials: CB
authors.lastname: Olivier
authors.forename: P
authors.initials: P
authors.lastname: Diehl
authors.forename: C
authors.initials: C
authors.lastname: Bode
authors.forename: M
authors.initials: M
authors.lastname: Moser
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D001241:Aspirin / Q000008:administration & dosage*; D002309:Cardiology / Q000592:standards*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000379:methods; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D001241:Aspirin